Tech article
“We’re not doing 30 bets a year”: Vijay Pande on betting small after running $4 billion at a16z
Publisher description: Vijay Pande — who left a16z's roughly $4 billion biotech practice last year to start the much smaller, AI-native VZVC — talks about why biology is finally shifting from a "discovery" science to an "engineering" one, why clinical trials are still brutally expensive, and why he thinks open, shared datasets (not walled-off ones) are what will actually let AI transform medicine.
TechCrunch | Aug 29, 2026 | Connie Loizos
Automated excerpt
That’s, I think, very much an aspiration. There have actually been very significant advances over those 10 years. What’s overhyped right now in AI and biotech?
Selected automatically from source text; not independently written or fact-checked. Read the original for full context.